Please provide your email address to receive an email when new articles are posted on . Douglas W. Jackson, MD, asks 4 questions of Joshua S. Dines, MD, about the history of PVNS. While it is an ...

A new targeted therapy has demonstrated "profound activity" in the treatment of pigmented villonodular synovitis (PVNS). This rare joint proliferative neoplasm involves the synovium of joints or ...

The powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease, ...

NEW YORK, NY, May 14, 2014 — A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I ...

Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. Methods: We conducted an international multi-institutional retrospective study to assess the activity ...

Reversing the oncogenic roles of misdirected chromatin remodeling: Mechanistic insights into the SS18-SSX fusion protein in synovial sarcoma. Results of the randomized phase III trial of trabectedin ...

We herein describe three cases of pigmented villonodular synovitis with chondroid metaplasia. Two cases involved the temporomandibular joint, whereas the remaining one case occurred in the hip joint.

A previously well 30 year old man presented with a short history of intra-articular mechanical locking, swelling, and anteromedial joint line pain. There was localised tenderness, and McMurray’s test ...

New York, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and ...

According to new data, a novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS) a rare neoplastic joint disorder. At the time of interim analysis, ...